TORONTO: An Ontario man battling Stage 4 melanoma is challenging the provincial government’s decision to deny funding for a potentially life-saving cancer treatment available outside Canada, arguing that bureaucratic delays could cost him his life.
Thirty-seven-year-old Alex Shved, a private equity professional and father of two young daughters, has been fighting melanoma since 2020. Despite undergoing several treatments and continuing to work while caring for his family, the cancer has now spread to his lungs and bones.
His oncologist has recommended tumour-infiltrating lymphocyte (TIL) therapy, an advanced immunotherapy that involves removing a patient’s tumour, extracting cancer-fighting immune cells, multiplying them in a laboratory, and reinfusing them after chemotherapy to help the body attack cancer more effectively.
Although Health Canada approved a commercial version of the therapy, known as lifileucel, in 2025, it is still undergoing reviews before provincial drug plans decide whether to provide public funding. That process could take several years.
Shved says he cannot afford to wait.
“I may not be medically fit by the time the treatment is approved, or I may simply not be alive,” he said.
His oncologist requested provincial approval for him to receive the therapy at the Moffitt Cancer Center in Florida, where treatment is estimated to cost approximately $1 million. The Ontario Ministry of Health denied the request, stating that the province’s Out-of-Country Prior Approval Program cannot be used to provide interim funding for treatments currently under review for public coverage.
Shved argues that the decision creates an unfair situation in which the province refuses funding today because it may fund the treatment in the future—long after patients with advanced cancers may have lost their opportunity.
Calling the decision impersonal and lacking transparency, Shved has appealed to the Health Services Appeal and Review Board, sought judicial review, filed Freedom of Information requests, and contacted numerous government officials seeking an explanation of how the decision was made.
Health Minister Sylvia Jones recently spoke with Shved after his case attracted media attention. According to Shved, he urged the minister to introduce expedited regulatory changes and noted that similar TIL therapy is available in countries such as Israel and Turkey at significantly lower costs than in the United States. While expressing sympathy, the minister reportedly advised that she could not intervene in an individual case but would discuss the matter with ministry officials.
In a written statement, the Ontario Ministry of Health said provinces participating in the pan-Canadian Pharmaceutical Alliance do not approve out-of-country funding for drugs still undergoing national price negotiations and funding reviews. The ministry added that Ontario has never approved such funding while a therapy remains under national review.
Health policy experts suggest the province is reluctant to pay substantially higher American prices before negotiations establish Canadian pricing. They note that patented medicines often cost two to three times more in the United States than in Canada and that governments must balance spending decisions across the health-care system.
Experts also point out that it typically takes nearly two years from Health Canada approval to provincial funding decisions, a timeline that includes clinical assessments, cost-effectiveness reviews, and price negotiations.
For Shved, however, time is a luxury he does not have.
While continuing to participate in an early-stage clinical trial and hoping for positive results, he says his fight extends beyond his own illness. He wants greater transparency and accountability in government decisions affecting critically ill patients seeking access to life-saving treatments.
Shved believes many patients facing similar circumstances may lack the strength, time, or resources to challenge such decisions. He says he feels a responsibility to pursue the case not only for himself but also for others who may face the same barriers in the future.